- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01945762
Observational Study to Evaluate Vandetanib in RET -/+ Patients With Metastatic Medullary Thyroid Cancer (Caprelsa104)
European, Observational, Prospective Study to Evaluate the Benefit/Risk of Vandetanib in RET Mutation Negative and Positive Patients With Symptomatic, Aggressive, Sporadic, Unresectable, Locally Advanced/Metastatic Medullary Thyroid Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a multinational, multicenter, non-interventional (observational) and prospective study. European countries where vandetanib is on the market will participate in the study.
This study is being conducted to fulfil the specific obligation post-authorisation measure for the conditional marketing authorisation. It is carried on to confirm in real life conditions the benefit/risk of vandetanib (CAPRELSA™) 300 mg, both in RET negative and RET positive patients with symptomatic, aggressive, sporadic, unresectable, locally advanced/metastatic MTC. The clinical benefit of vandetanib (CAPRELSA™) 300 mg has previously been established in a clinical trial (Study 58) on the basis of a clinically and statistically significant advantage in progression free survival (PFS) which was supported by a high response rate and substantial duration of response.
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Belgium, Belgium
- Investigational site Belgium
-
-
-
-
-
France, France
- Investigational site France
-
-
-
-
-
Germany, Germany
- investigational Site Germany
-
-
-
-
-
Italy, Italy
- Investigational Site Italy
-
-
-
-
-
Luxembourg, Luxembourg
- investigational Site Luxembourg
-
-
-
-
-
Netherlands, Netherlands
- Investigational site Netherlands
-
-
-
-
-
Spain, Spain
- investigational site Spain
-
-
-
-
-
United Kingdom, United Kingdom
- investigational Site United Kingdom
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
1. Signed informed consent 2. Male or female aged 18 years or above 3. Histological diagnosis of MTC 4. Patients with symptomatic and aggressive sporadic MTC, who have unresectable, locally advanced/metastatic disease. (The factors considered by the investigator to determine a patient's disease to be symptomatic and aggressive will be recorded in the CRF). 5. Measurable disease:
- assessment confirmed within the 12 weeks previous to start of treatment, and
- defined according to RECIST 1.1: at least one lesion, not irradiated, that can be accurately measured as ≥10 mm in the longest diameter (except lymph nodes which must have short axis ≥15 mm) with CT or MRI and which is suitable for accurate repeated measurements. Measurable lesions with calcifications should not be assessed as target lesions unless no other measurable lesion is available. 6. Known definite RET mutation status (definition according to section 3.2). The status should be:
- for patients prescribed with vandetanib: positive or negative
for patients not prescribed with vandetanib: negative RET mutation status must be determined from a tumour sample obtained within 18 months prior to enrollment. It is strongly recommended that a tissue sample obtained within 6 months prior to enrolment is used. 7. For patients newly prescribed vandetanib 300 mg, the prescription should be issued according to marketing authorisation and following the vandetanib Summary of Product Characteristics (SmPC) (Appendix B). The starting dose could be reduced to 200 mg in patients with moderate renal impairment
Exclusion criteria
- Current or planned inclusion/participation in a clinical trial
- Patients already receiving vandetanib or who have received vandetanib for their MTC before the study first visit
- Contraindications according to the vandetanib SmPC (not applicable for patients who do not receive vandetanib): (a) Patients with a QT interval corrected for heart rate (QTc) interval over 480 msec: (i) Congenital long QT syndrome (ii) Concomitant use of vandetanib with the following medicinal products known to also prolong the QT interval and / or induce Torsades de pointes: Arsenic, cisapride, erythromycin intravenous (IV), toremifene, mizolastine, moxifloxacin, Class I A and III antiarrhythmics (b) Currently pregnant or breast feeding (c) Hypersensitivity to the active substance or to any of the excipients (d) Severe renal impairment: creatinine clearance < 30 ml/minute calculated by Cockcroft-Gault formula. (See Appendix D). (e) Serum bilirubin greater than 1.5 x the upper limit of reference range (ULRR) (f) Potassium, magnesium or calcium outside the normal laboratory range
Study Plan
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
1. patient cohorts (40 patients/cohort)
RET positive patient cohorts
|
Vandetanib commercial tablets
Other Names:
|
2. patient cohorts (40 patients/cohort)
RET negative patient cohorts
|
Vandetanib commercial tablets
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Assessment of Objective Response Rate
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Assessment of Objective Response Rate [using Response Evaluation Criteria In Solid Tumours (RECIST) 1.1]
|
From enrollment until study completion, assessed up to 38 months
|
Assessment of Disease control rate
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Assessment of Disease control rate [using Response Evaluation Criteria In Solid Tumours (RECIST) 1.1]
|
From enrollment until study completion, assessed up to 38 months
|
Assessment of Duration of Response
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Assessment of Duration of Response (using RECIST 1.1)
|
From enrollment until study completion, assessed up to 38 months
|
Assessment of Progression Free Survival
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Assessment of Progression Free Survival (using RECIST 1.1)
|
From enrollment until study completion, assessed up to 38 months
|
Evaluation of Safety by assessment of QTc prolongations
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Assessment of QTc prolongations
|
From enrollment until study completion, assessed up to 38 months
|
Evaluation of Safety by assessment of Adverse Events
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Assessment of Adverse Events
|
From enrollment until study completion, assessed up to 38 months
|
Evaluation of Safety by assessment of vital signs
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Assessment of Vital signs
|
From enrollment until study completion, assessed up to 38 months
|
Evaluation of Safety by assessment of laboratory data
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Assessment of Laboratory data
|
From enrollment until study completion, assessed up to 38 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Patient Characteristics
Time Frame: From enrollment until study completion, assessed up to 38 months
|
Patient demographics and medical history / Disease characteristics / Death / Treatment information
|
From enrollment until study completion, assessed up to 38 months
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Behavioral Symptoms
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Adenocarcinoma
- Carcinoma
- Neoplasms, Glandular and Epithelial
- Endocrine System Diseases
- Endocrine Gland Neoplasms
- Head and Neck Neoplasms
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Neuroendocrine Tumors
- Aggression
- Thyroid Diseases
- Thyroid Neoplasms
- Carcinoma, Neuroendocrine
Other Study ID Numbers
- D4200C00104
- OBS14778 (Other Identifier: Sanofi)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Symptomatic, Aggressive, Sporadic, Unresectable, Locally
-
Shanghai Runshi Pharmaceutical Technology Co., LtdJilin Provincial Tumor HospitalRecruitingLocally Advanced Unresectable CarcinomaChina
-
Gilead SciencesEverest MedicinesActive, not recruitingLocally Advanced or Metastatic Unresectable Urothelial CancerUnited States, Belgium, France, Spain, United Kingdom, Korea, Republic of, Czechia, Germany, Israel, China, Italy, Australia, Hong Kong, Taiwan, Portugal, Singapore, Croatia, Greece, Turkey, Sweden, Switzerland, Canada, Austria, Bulgaria and more
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States
-
Hangzhou Sumgen Biotech Co., Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsChina
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyActive, not recruitingMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, China, Spain, Japan, United Kingdom
-
EMD Serono Research & Development Institute, Inc.Merck KGaA, Darmstadt, GermanyTerminatedMetastatic or Locally Advanced Unresectable Solid TumorsUnited States, Canada
-
Txinno Bioscience Inc.RecruitingLocally Advanced (Unresectable) or Metastatic Solid TumorsKorea, Republic of
-
Innovent Biologics (Suzhou) Co. Ltd.Not yet recruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingLocally Advanced Unresectable or Metastatic Solid TumorsAustralia
-
Jiangsu Simcere Pharmaceutical Co., Ltd.Shanghai Xianxiang Medical Technology Co., Ltd.; Simcere ZaimingRecruitingLocally Advanced Unresectable or Metastatic Solid TumorUnited States, China
Clinical Trials on Vandetanib 300 mg
-
Genzyme, a Sanofi CompanyTerminated
-
Bausch Health Americas, Inc.CompletedRheumatoid ArthritisUnited States
-
Novartis PharmaceuticalsCompletedChronic Plaque PsoriasisUnited States
-
Radboud University Medical CenterUnknownAcute Kidney Injury | Critically Ill ChildrenNetherlands
-
King Abdullah International Medical Research CenterNovartisTerminatedMyeloid Leukemia, ChronicSaudi Arabia
-
National Cancer Institute (NCI)CompletedRenal Cancer | Von Hippel LindauUnited States
-
CVI PharmaceuticalsUnknown
-
Cognition TherapeuticsNational Institute on Aging (NIA)CompletedAlzheimer DiseaseUnited States
-
City Clinical Hospital No.52 of Moscow Healthcare...Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry...Active, not recruitingCoronavirus InfectionsRussian Federation